In 2023, the trade exchange (includes international purchases and sales) of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes was US$2.28B.
In 2023, the states with the most international sales in Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were Estado de México (US$86.1M), Ciudad de México (US$39.1M), Baja California (US$37.8M), Jalisco (US$31.9M), and Sonora (US$1.26M).
The states with the most international purchases in 2023 were Ciudad de México (US$1.69B), Estado de México (US$293M), Jalisco (US$36.7M), Baja California (US$33.7M), and Morelos (US$12.8M).
In 2023, the main commercial destinations of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were France (US$84.6M), United States (US$51.6M), Guatemala (US$6.37M), Belgium (US$5.94M), and Dominican Republic (US$5.65M).
The main commercial origins of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes in 2023 were United States (US$378M), Switzerland (US$271M), Germany (US$263M), Puerto Rico (US$204M), and France (US$190M).
In the global context, the main exporting countries of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes in 2022 were Ireland (US$47.3B), United States (US$46.8B), and Belgium (US$46.5B). In the same year, the main importing countries of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were United States (US$67.8B), Germany (US$40.9B), and Belgium (US$21.6B).